Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-13

Study Completion Date

2024-01-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is being conducted to evaluate the pharmacokinetic, and safety of two sizes of SHR4640 tablets in healthy adults, to explore the bioequivalence between two sizes of SHR4640 tablets.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects

NCT03273088

Phase 1 Bioequivalence

COMPLETED PHASE1

Comparative Bioavailability Study of Tablet and Granule Formulations of ADC189 and the Study of Ultra-high Dose

NCT06428903

Healthy Volunteer

COMPLETED PHASE1

Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults

NCT04886050

Gout Hyperuricemia

COMPLETED PHASE1

A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers

NCT03860948

Bioequivalence

COMPLETED PHASE1

Dapagliflozin Tablet 10 mg Relative to Forxiga® Tablets 10 mg

NCT06233045

Healthy Subjects

NOT_YET_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperuricemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized, Open, Single Dose, Two Sequences, Two Cycles, Self-Crossover Control

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment group A

Group Type EXPERIMENTAL

SHR4640

Intervention Type DRUG

SHR4640, 2.5mg\*4 - 10mg\*1

Treatment group B

Group Type EXPERIMENTAL

SHR4640

Intervention Type DRUG

SHR4640, 10mg\*1 - 2.5mg\*4

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SHR4640

SHR4640, 2.5mg\*4 - 10mg\*1

Intervention Type DRUG

SHR4640

SHR4640, 10mg\*1 - 2.5mg\*4

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able and willing to provide a written informed consent.
2. 18 years to 45 years (inclusive).
3. Body weight should above 45 kg, and body mass index should be between 19 and 28 kg/m2 (inclusive).
4. The physical examination, vital signs, laboratory examination and electrocardiogram are not abnormal or abnormal but with no clinical significance.

Exclusion Criteria

1. Pregnant or nursing women.
2. No birth control 1 weeks before screening or until one week after SHR4640 administration.
3. Average daily alcohol consume more than 14g for female or more than 28g for male within 1 month before screening, or baseline alcohol screening is positive.
4. Smokers (average daily smoking of 5 cigarettes or more in the 3 months before screening).
5. Subject with a history of substance abuse and drug abuse.
6. The investigators determined that other conditions were inappropriate for participation in this clinical trial.
7. sUA level ≥480 μmol/L.
8. eGFR \< 90 mL/min/1.73 m2.
9. Positive result for human immunodeficiency virus (HIV), hepatitis C virus antibody, or syphilis antibody, or hepatitis B surface antigen.
10. 12-lead electrocardiogram (ECG) showed abnormal and clinically significant.
11. Cardiovascular, neuropsychiatric, respiratory, digestive tract, endocrine and other systemic diseases within 1 year before screening, which were judged to be serious by the investigators.
12. History of hypersensitivity to SHR4640 or its analogues.
13. History or suspected crystals or stones in the urinary system during the screening period of B-ultrasound.
14. History of been diagnosed with acute kidney injury in the past or screening period.
15. Had undergone major surgery within 3 months prior to screening, or have not recovered from surgery, or plan major surgery during the study.
16. Blood donation within 1 month before screening; Or patients with trauma or major surgical procedures who donated blood or lost blood \> 400 mL in the 3 months prior to screening.
17. Has unsuitable venous for blood sampling.
18. Received the last dose of a study drug (or treatment with a medical device) within 3 months or 5 T1/2 (whichever is longer) of the screening or are currently participating in another study of a study drug (or medical device).
19. Have received or been exposed to other live vaccines or live attenuated vaccines within 3 months prior to Day 1, or who plan to receive live vaccines or live attenuated vaccines during the study.
20. Consumes grapefruit and/or poppy seed within 48 hours before SHR4640 administration.
21. Taken any prescription drugs, over-the-counter drugs, herbal medicines or food supplements within 2 weeks before screening.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes